Ning Xia
夏宁
Ning Xia is the founder and CEO of Chemical.AI (智化科技), a Wuhan-based company that applies artificial intelligence to chemical synthesis in drug discovery . He holds a PhD in organic chemistry from the French Academy of Sciences and has a dual background in chemistry and computer science, having spent over a decade working at the intersection of computation and chemical synthesis . He founded Chemical.AI in 2018 , and by 2021 the company was described in FreeS Fund coverage as a leading player in AI-assisted chemical synthesis, with products deployed at top global pharmaceutical companies and a closed-loop model combining data, CRO services, and robotics . He has been a recurring speaker at FreeS Fund's biotech and pharmaceutical investment summits, where he has discussed AI's role in drug R&D alongside peers from companies like XtalPi and Metis Pharmaceuticals .
AI-generated — may contain errors, please verify.
Coverage
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
峰瑞资本·Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
峰瑞资本·"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
峰瑞资本·FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
峰瑞资本·Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
峰瑞资本·How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
峰瑞资本·FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
峰瑞资本·New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
峰瑞资本·Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
峰瑞资本·Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
峰瑞资本·Why Is AI Drug Discovery So Hot? And How Long Will It Stay Hot? | FreeS Fund Events & Research Recs
Three Slightly Brain-Burning Little Gifts
峰瑞资本·How to Navigate Black Swans: We Spoke with Six Founders
Through the Hundreds of Hardships of Entrepreneurship: A Founder Must Be a Problem-Solver
峰瑞资本·
